CardioQ-ODM in Keyhole Surger

RNS Number : 7639E

Deltex Medical Group PLC

01 October 2008

 



Deltex Medical Group plc

New data confirms benefit of CardioQ-ODM in keyhole surgery

1 October 2008 - Deltex Medical Group plc ('Deltex Medical' or the 'Company'), the UK's leading haemodynamic monitoring company and global leader in oesophageal Doppler monitoring ('ODM'), notes the first presentation of important new clinical data on the use its CardioQ-ODM system in keyhole surgery.

Nearly 1,000 colorectal surgeons attending the annual meeting of the European Society of Coloproctology in Nantes, France from 24 to 27 September 2008 heard doctors from Darent Valley Hospital in Kent, England present the outcomes of patients undergoing keyhole bowel surgery over a five year period.

The results covered 238 patients over five years of whom 144 had a CardioQ-ODM and 94 did not. The CardioQ-ODM group of patients was found to have been generally sicker and higher risk prior to surgery yet still did better on the following bases than those fitter, lower risk patients denied the CardioQ-ODM:

• Lower hospital stay (7 days vs 9)

• Lower mortality (1 patient vs 3)

• Lower major complications (6 vs 31)

• Lower total complications (20 vs 43)

• Lower operative time (162 minutes vs 180)

Furthermore, in just five cases, being less than 3.5% of those cases where CardioQ-ODM was used did the surgical team need to convert the procedure from keyhole to open surgery compared to nearly 25% of cases where CardioQ-ODM was not used. The National Institute for Health and Clinical Excellence (NICE) reports that 20% of these cases are converted from keyhole to open surgery and that such conversion is associated with higher blood loss, longer hospital stay and greater risk of tumour recurrence.

Deltex Medical's Chief Executive, Andy Hill commented:

'This powerful body of data shows that the addition of CardioQ-ODM makes laparoscopic surgery cost effective as well as clinically effective.  We expect NICE to take these findings into account when it reconsiders its technology appraisal of the cost effectiveness of the keyhole approach to colorectal cancer surgery, which is scheduled to commence by September 2009.'

For further information, please contact:-

Deltex Medical Group plc Nigel Keen, Chairman Andy Hill, Chief Executive Ewan Phillips, Finance Director	01243 774 837 [e-mail] [e-mail] [e-mail]
Gavin Anderson & Company Deborah Walter Robert Speed	0207 554 1400 [e-mail] [e-mail]
Nominated Adviser & Broker Charles Stanley Securities Philip Davies  Russell Cook	020 7149 6000 [e-mail] [e-mail]

 Notes for Editors

Deltex Medical manufactures and markets the CardioQ-ODM™ monitor, which uses disposable ultra-sound probes inserted into the oesophagus to determine the amount of blood being pumped around the body - 'circulating blood volume'. Reduced circulating blood volume is known as hypovolaemia, which leads to insufficient oxygen being delivered to the organs. This causes medical complications including peripheral and major organ failure which can lead to death. Hypovolaemia, which is akin to severe dehydration, affects virtually every patient having surgery because of the combined effects of pre-operative starvation, the impact of the anaesthetic agents and trauma from the surgery itself. Using fluids and drugs, guided by the CardioQ-ODM, to optimise the amount of circulating blood significantly reduces post-operative complications allowing patients to make a faster, more complete recovery and return home earlier.

The CardioQ-ODM incorporates the Company's proprietary software and a small diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is used for transmitting and receiving an ultra-sound signal. By using this technology, the CardioQ-ODM provides clinicians with the ability to haemodynamically optimise critically ill patients and those undergoing routine moderate to major surgery through the controlled administration of fluid and drugs. Haemodynamic optimisation has been scientifically proven to improve the speed and quality of patient recovery and reduce hospital stay.

There are already over 1,500 CardioQ-ODMs currently in use in hospitals worldwide and distribution arrangements are in place in over 30 countries. In addition, there are currently more than 100 clinical publications on the use of the CardioQ-ODM which have repeatedly:-

• Validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the technology works

• Proved that the CardioQ-ODM works in a wide range of surgical procedures

• Demonstrated that the Company's technology provides significant health and economic benefits by helping to reduce post-operative complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients.

The SupraQ™ is an entirely non-invasive device which uses an ultrasound probe held at the base of the patient's neck to track the flow of blood in the aorta; it presents the same data as the CardioQ-ODM in a similar format and is used for taking snapshots or monitoring over short periods.

 

END

 

 

NRAWUUUWBUPRGQU